Arrhythmogenic right ventricular cardiomyopathy resident survival guide: Difference between revisions
Steven Bellm (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
<div style="width: 80%;"> | <div style="width: 80%;"> | ||
__NOTOC__ | __NOTOC__ | ||
Line 22: | Line 21: | ||
==Overview== | ==Overview== | ||
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disease characterized by myocyte loss and fibro-fatty tissue replacement of the right ventricular myocardium. This puts patients into risk of life-threatening ventricular [[arrhythmias]] and slowly progressive ventricular dysfunction. The diagnostic is challenging. Diagnosis of [[ARVC]] relays on a scoring system, with major or minor criteria on the Revised Task Force Criteria. Pharmacologic treatment of | Arrhythmogenic right ventricular [[cardiomyopathy]] (ARVC) is a genetic disease characterized by myocyte loss and fibro-fatty tissue replacement of the right ventricular myocardium. This puts patients into risk of life-threatening ventricular [[arrhythmias]] and slowly progressive ventricular dysfunction. The diagnostic is challenging. Diagnosis of [[ARVC]] relays on a scoring system, with major or minor criteria on the Revised Task Force Criteria. Pharmacologic treatment of [[arrhythmia]]s, catheter ablation of [[ventricular tachycardia]], and ICD are main goals of the treatment.<ref name="pmid25548613">{{cite journal| author=Pinamonti B, Brun F, Mestroni L, Sinagra G| title=Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges. | journal=World J Cardiol | year= 2014 | volume= 6 | issue= 12 | pages= 1234-44 | pmid=25548613 | doi=10.4330/wjc.v6.i12.1234 | pmc=PMC4278158 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25548613 }} </ref> | ||
==Classification== | ==Classification== | ||
Line 147: | Line 146: | ||
==Treatment== | ==Treatment== | ||
❑ Prevention of sudden death: | ❑ Prevention of sudden death: | ||
:❑ <u>Risk assessment:</u>Cardiac arrest, syncope, young age, malignant family history, participation in competitive sports, VT, severe right ventricular dysfunction, Left ventricular involvement, and QRS dispersion of 40 ms or more | :❑ <u>Risk assessment:</u>[[Cardiac arrest]], [[syncope]], young age, malignant family history, participation in competitive sports, VT, severe right ventricular dysfunction, Left ventricular involvement, and QRS dispersion of 40 ms or more | ||
:❑ <u>Asymptomatic patients or healthy gene carriers:</u> Check of medical history, basal 12-lead ECG, 24-h Holter monitoring, exercise testing, and echocardiography on a regular basis | :❑ <u>Asymptomatic patients or healthy gene carriers:</u> Check of medical history, basal 12-lead ECG, 24-h Holter monitoring, exercise testing, and echocardiography on a regular basis | ||
Line 153: | Line 152: | ||
:❑ <u>Patients with haemodynamically stable [[arrhythmias]]:</u> Beta blockers or/and class III antiarrhythmic drugs (sotalol and amiodarone), use assessed by electrophysiologic testing | :❑ <u>Patients with haemodynamically stable [[arrhythmias]]:</u> Beta blockers or/and class III antiarrhythmic drugs (sotalol and amiodarone), use assessed by electrophysiologic testing | ||
:❑ <u>Patients with cardiac arrest, [[syncope]], or haemodynamically poorly-tolerated VT despite antiarrhythmic therapy:</u>Treatment with ICD | :❑ <u>Patients with [[cardiac arrest]], [[syncope]], or haemodynamically poorly-tolerated VT despite antiarrhythmic therapy:</u>Treatment with ICD | ||
:❑ <u>Patient with early and severe right ventricular dysfunction or advanced disease with biventricular involvement:</u> Consider prophylactic ICD implantation | :❑ <u>Patient with early and severe right ventricular dysfunction or advanced disease with biventricular involvement:</u> Consider prophylactic ICD implantation | ||
Line 159: | Line 158: | ||
❑ <u>Patients with [[heart failure]]:</u> [[Diuretics]], [[angiotensin-converting-enzyme]] inhibitors and [[digitalis]], and [[anticoagulants]] | ❑ <u>Patients with [[heart failure]]:</u> [[Diuretics]], [[angiotensin-converting-enzyme]] inhibitors and [[digitalis]], and [[anticoagulants]] | ||
❑ <u>Patients with refractory congestive heart failure or untreatable ventricular arrhythmias</u>:Heart transplantation as final therapeutic | ❑ <u>Patients with refractory congestive heart failure or untreatable ventricular arrhythmias</u>:Heart transplantation as final therapeutic option | ||
❑ Restriction of physical exercise for all patients<ref name="pmid25548613">{{cite journal| author=Pinamonti B, Brun F, Mestroni L, Sinagra G| title=Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges. | journal=World J Cardiol | year= 2014 | volume= 6 | issue= 12 | pages= 1234-44 | pmid=25548613 | doi=10.4330/wjc.v6.i12.1234 | pmc=PMC4278158 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25548613 }} </ref> | ❑ Restriction of physical exercise for all patients<ref name="pmid25548613">{{cite journal| author=Pinamonti B, Brun F, Mestroni L, Sinagra G| title=Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges. | journal=World J Cardiol | year= 2014 | volume= 6 | issue= 12 | pages= 1234-44 | pmid=25548613 | doi=10.4330/wjc.v6.i12.1234 | pmc=PMC4278158 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25548613 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[CME Category::Cardiology]] | |||
[[Category:Resident survival guide]] | [[Category:Resident survival guide]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Latest revision as of 20:28, 29 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Steven Bellm, M.D. [2]
Arrhythmogenic right ventricular cardiomyopathy resident survival guide Microchapters |
---|
Overview |
Classification |
Causes |
FIRE |
Diagnosis |
Treatment |
Overview
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disease characterized by myocyte loss and fibro-fatty tissue replacement of the right ventricular myocardium. This puts patients into risk of life-threatening ventricular arrhythmias and slowly progressive ventricular dysfunction. The diagnostic is challenging. Diagnosis of ARVC relays on a scoring system, with major or minor criteria on the Revised Task Force Criteria. Pharmacologic treatment of arrhythmias, catheter ablation of ventricular tachycardia, and ICD are main goals of the treatment.[1]
Classification
Stages of disease
- Concealed phase: Subclinical asymptomatic phase
- Overt electrical disorder: Palpitations, syncope and typically with symptomatic ventricular arrhythmias of RV
- RV failure: Progressive loss of RV myocardium due to fibro-fatty replacement impairs RV function, pump failure
- Biventricular failure: Involvement of the interventricular septum and LV causing congestive heart failure (HF)[1]
Patterns of expression
- Classic ARVC:Increased RV to LV volume ratio, more severe involvement of the RV, negative anterior T waves and ventricular arrhythmias with LBBB morphology
- Left-dominant arrhythmogenic cardiomyopathy (LDAC):Predominantly involves the LV, LV wall motion abnormalities, chamber dilation, systolic impairment, and late gadolinium enhancement (LGE), ventricular arrhythmias of right bundle branch block (RBBB) morphology, (infero)-lateral T-wave inversion
- Biventricular arrhythmogenic:Early and parallel involvement of the RV and LV, biventricular dilation and systolic impairment, ventricular arrhythmias of both RBBB and LBBB configuration may occur, ratio of RV to LV volume remains close to 1[1]
Causes
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disease.
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention. The diagnosis of ARVC is currently based on the presence of major and minor standardised Task Force Criteria. Diagnosis is established when two major, one major plus two minor, or four minor criteria from different groups are fulfilled.[1]
❑ Global and/or regional dysfunction and structural alterations:
Major
- ❑ Severe dilatation and reduction of right ventricular ejection fraction with no (or only mild) left ventricular impairment
- ❑ Localised right ventricular aneurysms (akinetic or dyskinetic areas with diastolic bulging)
- ❑ Severe segmental dilatation of the right ventricle
Minor
- ❑ Mild global right ventricular dilatation and/or ejection fraction reduction with normal left ventricle
- ❑ Mild segmental dilatation of the right ventricle
- ❑ Regional right ventricular hypokinesia
❑ Tissue characterisation of wall
Major
- ❑ Fibrofatty replacement of myocardium on endomyocardial biopsy
❑ Repolarisation abnormalities
Minor
- ❑ Inverted T waves in right precordial leads (V2 and V3) (people aged >12 years, in absence of right bundle branch block)
❑ Depolarisation/conduction abnormalities
Major
- ❑ Epsilon waves or localised prolongation (>110 ms) of the QRS complex in right precordial leads (V1–V3)
Minor
- ❑ Late potentials (signal-averaged ECG)
❑ Arrhythmias
Major
- ❑ Arrhythmias listed below plus T-wave abnormalities—see III Repolarisation abnormalities
Minor
- ❑ Left bundle branch block type ventricular tachycardia (sustained and nonsustained) (ECG, Holter, exercise testing)
- ❑ Frequent ventricular extrasystoles (>1000/24-h) (Holter)
❑ Family history
Major
- ❑ Familial disease confirmed at necropsy or surgery
Minor
- ❑ Family history of premature sudden death (<35 years) due to suspected ARVC
- ❑ Family history of ARVC (clinical diagnosis based on present criteria)
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1]
History and symptoms: ❑ Hints for etiology (family history)
❑ Duration and onset of illness/ symptoms
| |||||||||||||||||||
Physical examination: ❑ Vital signs:
❑ General appearance:
❑ Heart:
❑ Lungs:
❑ Extremities:
| |||||||||||||||||||
Laboratory findings: ❑ Complete blood count
| |||||||||||||||||||
Imaging and additional tests: ❑ Noninvasive imaging and tests:
If diagnosis is not clear by other methods ❑ Invasive imaging and tests:
If diagnosis is not clear by other methods
If diagnosis is not clear by other methods
| |||||||||||||||||||
Treatment
❑ Prevention of sudden death:
- ❑ Risk assessment:Cardiac arrest, syncope, young age, malignant family history, participation in competitive sports, VT, severe right ventricular dysfunction, Left ventricular involvement, and QRS dispersion of 40 ms or more
- ❑ Asymptomatic patients or healthy gene carriers: Check of medical history, basal 12-lead ECG, 24-h Holter monitoring, exercise testing, and echocardiography on a regular basis
- ❑ Patients with haemodynamically stable arrhythmias: Beta blockers or/and class III antiarrhythmic drugs (sotalol and amiodarone), use assessed by electrophysiologic testing
- ❑ Patients with cardiac arrest, syncope, or haemodynamically poorly-tolerated VT despite antiarrhythmic therapy:Treatment with ICD
- ❑ Patient with early and severe right ventricular dysfunction or advanced disease with biventricular involvement: Consider prophylactic ICD implantation
❑ Patients with heart failure: Diuretics, angiotensin-converting-enzyme inhibitors and digitalis, and anticoagulants
❑ Patients with refractory congestive heart failure or untreatable ventricular arrhythmias:Heart transplantation as final therapeutic option
❑ Restriction of physical exercise for all patients[1]